Antibody Information

General Information of This Antibody
Antibody ID
ANI0JQASB
Antibody Name
Adalimumab
Brand Name
HUMIRA
Organization
AbbVie, Inc.; Eisai Co., Ltd.
Indication
Crohn's disease; Rheumatoid arthritis; Ankylosing spondylitis; Psoriatic arthritis; Juvenile Idiopathic Arthritis; Hidradenitis suppurativa; Ulcerative colitis; Uveitis
Approval Date
Dec. 2002
Synonyms
ABP-501; ABRILADA; ADALIMUMAB; ADALIMUMAB ADAZ; ADALIMUMAB-ADAZ; ADALIMUMAB ADBM; ADALIMUMAB-ADBM; ADALIMUMAB AFZB; ADALIMUMAB-AFZB; ADALIMUMAB AQVH; ADALIMUMAB-AQVH; ADALIMUMAB ATTO; ADALIMUMAB-ATTO; ADALIMUMAB BETA; DALIMUMAB BIOSIMILAR (ALVOTECH); ADALIMUMAB BIOSIMILAR (AVT02); ADALIMUMAB BIOSIMILAR (CELLTRION); ADALIMUMAB BIOSIMILAR (CT-P17); ADALIMUMAB BIOSIMILAR (FKB-327); ADALIMUMAB BIOSIMILAR (ZRC-3197); ADALIMUMAB BWWD; ADALIMUMAB-BWWD; ADALIMUMAB-FKJP; ADALIMUMAB (GENETICAL RECOMBINATION); ADALIMUMAB (HUMIRA); AMJEVITA; AVT02; AVT-02; BCD-057; BI695501; BI 695501; BI-695501; CHS-1420; CT-P17; CYLTEZO; D2E7; EXEMPTIA; FKB327; FKB-327; GP2017; GP-2017; HADLIMA; HLX03; HLX-03; HULIO; HYRIMOZ; LU200134; LU-200134; M923; M-923; MSB11022; MSB-11022; ONS-3010; TRUDEXA; YUSIMRY; ZRC3197; ZRC-3197
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1-kappa
Antigen Name
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)
  Antigen Info 
ChEMBI ID
CHEMBL1201580
PDB ID
3wd5 , 4nyl , 6cr1
DrugBank ID
DB00051
Drug Central ID
4904
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDY
ADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVS
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD
ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPG
    Click to Show/Hide
Heavy Chain Varible Domain
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDY
ADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVS
S
    Click to Show/Hide
Heavy Chain CDR 1
GFTFDDYA
    Click to Show/Hide
Heavy Chain CDR 2
ITWNSGHI
    Click to Show/Hide
Heavy Chain CDR 3
AKVSYLSTASSLDY
    Click to Show/Hide
Light Chain Sequence
DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPS
RFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain Varible Domain
DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPS
RFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK
    Click to Show/Hide
Light Chain CDR 1
QGIRNY
    Click to Show/Hide
Light Chain CDR 2
AAS
    Click to Show/Hide
Light Chain CDR 3
QRYNRAPYT
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
ABBV-154 [Phase 2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05068284  Clinical Status Phase 2
Clinical Description
A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-154 in subjects with moderately to severely active crohn's disease (CD): aim-cd.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT04972968  Clinical Status Phase 2
Clinical Description
A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of ABBV-154 in subjects with polymyalgia rheumatica (PMR) dependent on glucocorticoid treatment.
Experiment 3 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT04888585  Clinical Status Phase 2
Clinical Description
A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-154 in subjects with moderately to severely active rheumatoid arthritis with inadequate response to biologic and/or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsdmards).
Experiment 4 Reporting the Activity Date of This ADC [4]
Related Clinical Trial
NCT Number NCT05556226  Clinical Status Phase 1
Clinical Description
A phase 1 study in healthy subjects to evaluate the relative bioavailability of ABBV-154.
References
Ref 1 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD, NCT05068284
Ref 2 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, NCT04972968
Ref 3 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs), NCT04888585
Ref 4 A Phase 1 Study in Healthy Subjects to Evaluate the Relative Bioavailability of ABBV-154, NCT05556226

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.